Abstract
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation. Methods: A total of 1,871 patients with de novo TIPS implantation for ascites or secondary prophylaxis of variceal bleeding were recruited retrospectively. The study cohort was divided into a training set (80% of study patients; n = 1,496) and a validation set (20% of study patients; n = 375). Further, patients with early (preemptive) TIPS implantation due to variceal bleeding were included as another validation cohort (n = 290). Medical data and overall survival (OS) were assessed. A Cox regression model was used to create an alternative prediction model, which includes significant prognostic factors. Results: Age, bilirubin, albumin and creatinine were the most important prognostic factors. These parameters were included in a new score named the Freiburg index of post-TIPS survival (FIPS). The FIPS score was able to identify high-risk patients with a significantly reduced median survival of 5.0 (3.1–6.9) months after TIPS implantation in the training set. These results were confirmed in the validation set (median survival of 3.1 [0.9–5.3] months). The FIPS score showed better prognostic discrimination compared to the Child-Pugh, MELD, MELD-Na score and the bilirubin-platelet model. However, the FIPS score showed insufficient prognostic discrimination in patients with early TIPS implantation. Conclusions: The FIPS score is superior to established scoring systems for the identification of high-risk patients with a worse prognosis following elective TIPS implantation. Lay summary: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) is a safe and effective treatment for patients with cirrhosis and clinically significant portal hypertension. However, risk stratification is a major challenge in these patients as currently available scoring systems have major drawbacks. Age, bilirubin, albumin and creatinine were included in a new risk score which was named the Freiburg index of post-TIPS survival (FIPS). The FIPS score can identify patients at high risk and may guide clinical decision making.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Hepatology |
| Jahrgang | 74 |
| Ausgabenummer | 6 |
| Seiten (von - bis) | 1362-1372 |
| Seitenumfang | 11 |
| ISSN | 0168-8278 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 06.2021 |
Fördermittel
DB, LS and TB are supported by the Berta-Ottenstein-Programme , Faculty of Medicine, University of Freiburg. HL is supported by the IMM-PACT Programme, Faculty of Medicine, University of Freiburg , JT was supported by Deutsche Forschungsgemeinschaft ( SFB TRR57 P18 & CRC1382 A09 ) H2020 European Institute of Innovation and Technology ( 668031 ; 825694 ; 847949 ) H2020 Societal Challenges ( 731875 ) and CELLEX Foundation (PREDICT). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript. MP is supported by grants from the Ernst-und-Berta Grimmke Foundation ( Lfd.Nr.5/19 ) and BONFOR research program of the University of Bonn (grant- ID 2020-2A-07 ). DB, LS and TB are supported by the Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg. HL is supported by the IMM-PACT Programme, Faculty of Medicine, University of Freiburg, JT was supported by Deutsche Forschungsgemeinschaft (SFB TRR57 P18 & CRC1382 A09) H2020 European Institute of Innovation and Technology (668031; 825694; 847949) H2020 Societal Challenges (731875) and CELLEX Foundation (PREDICT). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript. MP is supported by grants from the Ernst-und-Berta Grimmke Foundation (Lfd.Nr.5/19) and BONFOR research program of the University of Bonn (grant-ID 2020-2A-07).JT: Grants: Gore, Consultant: Martins Pharma, Ironwood, Gore, Alexion, BMS, Grifols, Sequana Medicals, Versantis, Sponsored lectures (National or International): Gilead, Gore, Alexion, BMS, Grifols, Sequana Medicals, Norgine, Intercept. DB: Consultant: Bayer Healthcare, Boston Scientific, Shionogi. Lectures: Falk Foundation. LS: Lectures: Falk Foundation. RK: Consultant: Boston Scientific, Bristol-Myers Squibb, Guerbet, Roche, and SIRTEX. Lectures: BTG, Guerbet, Ipsen, SIRTEX, MSD Sharp & Dohme. MS: Consultant: Bayer Healthcare, L.W.Gore Lectures: Falk Foundation.
| Träger | Trägernummer |
|---|---|
| BONFOR | |
| Berta-Ottenstein Programme | |
| Ernst-und-Berta Grimmke Foundation | Lfd.Nr.5/19 |
| PREDICT | |
| Falk Foundation | |
| Gilead Sciences | |
| Fundación Cellex | |
| Merck Sharp and Dohme | |
| H2020 Societal Challenges | 731875 |
| H2020 European Institute of Innovation and Technology | 847949, 668031, 825694 |
| Deutsche Forschungsgemeinschaft | SFB TRR57 P18, CRC1382 A09 |
| Rheinische Friedrich-Wilhelms-Universität Bonn | 2020-2A-07 |
| Sirtex Medical |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 9 – Industrie, Innovation und Infrastruktur
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Biomedizintechnik
DFG-Fachsystematik
- 2.22-30 Radiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver